◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-FOR-NOW MEDIUM

Neboglamine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

Wrong compound at the wrong time for Dylan — mechanism is interesting (the only non-direct-agonist way to raise NMDA-glycine-site tone, theoretically activity-dependent and therefore safer than direct agonists), but human evidence in healthy adults is essentially zero, the development program has been stalled at Phase 2 since ~2010-2015 with no public readout of cognitive endpoints, anecdotal corpus is one or two YouTube reviews and no real Reddit/forum body, and stacking a novel NMDA-glycine PAM with TAK-653 (AMPA PAM) was already flagged in the encyclopedia as too aggressive (two unproven glutamate enhancers). Verdict would upgrade to WATCH-LIST if Rottapharm/successor publishes Phase 2 cognitive data with cleanly positive MATRICS/PANSS-cognition signal AND independent lab-grade COA-verified vendor product becomes routine; would upgrade to OPTIONAL-ADD only after FDA-pathway revival or replication by an unaffiliated group; would stay SKIP-FOR-NOW if no further development announcements appear by 2027.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    verdict-confidence MEDIUM. Three converging reasons: (1) no published cognitive-enhancement data in healthy adults, (2) Phase 2 program stalled without formal discontinuation = Bayesian concern that the readout was unfavorable, (3) MMA subconcussive impact + NMDA potentiation creates an unstudied interaction overlapping with the same concern that applies to TAK-653 — and stacking the two was already explicitly flagged in the encyclopedia as too aggressive. Defer indefinitely or until Rottapharm/successor publishes Phase 2 cognitive readouts and an independent group replicates in healthy adults.

  • 30-50, executive maintenance
    WATCH-LIST

    Same wait-for-data logic; less subconcussive concern. If clinical depression develops, neboglamine has at most a B-tier preclinical antidepressant signal — better-evidenced options exist (TAK-653, ketamine, esketamine, conventional antidepressants).

  • 50+, mild cognitive decline / early MCI
    WATCH-LIST

    Mechanism is theoretically interesting for cognition-enhancement in NMDA-hypofunction states, but no MCI/AD trial data. Other glycine-site approaches (luvadaxistat, iclepertin) have more advanced clinical programs. Memantine is the standard-of-care if NMDA modulation is targeted in this population.

  • Schizophrenia (negative symptoms / cognitive impairment associated with schizophrenia, CIAS)
    OPTIONAL

    pending FDA approval / Phase 3 advance. This is the indication the compound was designed for. If the program revives and produces clean Phase 2 cognitive data, this becomes the strongest case. As of 2026-05-05, no such data is in the public domain. Iclepertin has a more advanced CIAS program; luvadaxistat is more advanced; xanomeline + trospium (Cobenfy/KarXT) is FDA-approved for the schizophrenia symptoms it targets.

  • Anxiety-prone
    SKIP-FOR-NOW

    Glutamate-system amplification = theoretical anxiogenic signal. Anxiety-prone users have more downside risk from upper-dose-range overshoot.

  • Cocaine use disorder / addiction
    OPTIONAL

    pending Phase 3. Preclinical anti-addiction signal is real (drug-induced hypermotility inhibition); patent record (EP1940376) explicitly covers toxicodependency use. No published Phase 2 cocaine-dependence efficacy readout. Indication listed as "inactive" in current registry. For someone with active cocaine use disorder, more-evidenced options (contingency management, modafinil-as-substitute, NAC, baclofen) come first.

  • High athletic load, tested status
    SKIP

    Not on WADA prohibited list as of 2026 (not even on the radar — it's that obscure). Personal-import + research-chem identity is sample-failure liability.

  • Sleep-disordered
    SKIP-FOR-NOW

    Cortical-excitability angle + NRI activity at higher doses = unfavorable for someone running insomnia.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    Cerebrolysin is the better-evidenced choice; mechanistic argument for neboglamine in recovery is thin.

  • Strength/anabolic-focused
    NEUTRAL

    / not applicable. No anabolic mechanism. Cortical-excitability profile theoretically affects sleep recovery negatively at higher doses.

▸ Subjective experience (deep)

What clinical data says: The Phase 1 program reported "safe and well-tolerated within the dose range expected for efficacy." No subjective effect description has been published from the Phase 1/2 work.

What unsourced biohacker pages say (treat as low-confidence): Mild cognitive lift, clear-headed not stimulating, plausible antidepressant flavor over days-weeks, no euphoria, no dissociation, no obvious somatic side effects at 25-75 mg. Onset within 1-2 hours, duration ~4 hours (matching the reported half-life). At supratherapeutic doses (>100 mg) the weak NRI activity may add mild stimulant-flavored arousal — not described as comparable to atomoxetine or modafinil.

Honest summary for Dylan: The published acute experience is "no signal beyond placebo on tolerance metrics." No real-world cognitive-enhancement anecdote corpus exists. You cannot predict what this would feel like — you would be the corpus.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: unknown. No human chronic data beyond ~weeks. Preclinical chronic dosing not extensively published.
  • Recommended cycle: Not enough data to recommend a defensible cycle. If running, default to ≤2 weeks at lowest effective dose, then ≥2 weeks fully off, before reassessing. The short half-life makes washout easy (~24 hours covers >5 t½).
  • Reset protocol: ≥1 week off-drug for theoretical receptor renormalization. No data.
▸ Stacking deep dive

Synergistic with (theoretical / mechanism-aligned)

  • D-serine, glycine, sarcosine — same direction, but the whole point of a PAM over an agonist is that you don't need to load the agonist binding partner. Stacking would be redundant and would defeat the activity-dependent safety angle. Do not stack with direct glycine-site agonists.
  • Modafinil — orthogonal mechanism (DAT/NET inhibition + histaminergic + orexinergic). No formal data. Sequential layering (establish modafinil baseline first) is the only defensible pattern, same logic as TAK-653.

Avoid stacking with

  • TAK-653 — the encyclopedia's pre-existing flag stands. Two unproven glutamate-system amplifiers (AMPA PAM + NMDA glycine PAM) at the same time multiplies unknowns and provides no clean signal. Do not stack concurrently. If both are ever attempted, run sequentially with ≥4-week washout between trials.
  • Memantine — directly opposing on the NMDA axis (memantine = uncompetitive NMDA channel blocker; neboglamine = NMDA potentiator at the glycine co-agonist site). They don't cancel cleanly because they act on different sites of the same receptor — combination produces unpredictable net excitatory tone. Avoid concurrent. If memantine is ever introduced (e.g., for stim-tolerance management), neboglamine has to be off.
  • Agmatine — agmatine is a modest GluN2B-preferring NMDA antagonist + nNOS modulator. Same opposing-direction logic as memantine, weaker in absolute effect. For trial cleanliness, hold agmatine during a neboglamine pilot.
  • Ketamine, esketamine, dextromethorphan (high-dose), nitrous oxide, phencyclidine-class — all NMDA antagonists; opposing direction; do not run together.
  • D-cycloserine, D-serine, glycine high-dose, sarcosine, bitopertin/iclepertin/luvadaxistat — same-direction glutamate-system enhancers via different mechanisms. Stacking is mechanistically pointless and additively risky.
  • Tramadol, bupropion, pre-workout caffeine spikes >300 mg, designer cathinones, MDMA — additive cortical excitability / theoretical seizure-threshold issues. Not relevant for Dylan's V4/V5 stack but worth flagging.
  • First-gen AMPAkines (CX-516, sunifiram, unifiram, racetams in glutamate-system framing) — mechanism overlap; no point and adds risk.

Neutral / safe co-administration (best current understanding)

  • V4 OTC stack: DHA, magnesium glycinate/threonate, citicoline, NAC, phosphatidylserine, curcumin, rhodiola, theanine, glycine 3 g/day (note: this might mildly reload the glycine site and reduce neboglamine's apparent effect — theoretical only), D3+K2, beta-alanine, vitamin C, creatine.
    • Flag: NOW Foods Glycine 3 g/day in V4 is a borderline case — at oral 3 g, plasma glycine rises modestly, but synaptic glycine is heavily reuptake-controlled by GlyT1/GlyT2; the practical impact on neboglamine PD is probably small but unstudied. If running a clean neboglamine pilot, consider holding the glycine supplement (which is already flagged for V5 replacement with L-tryptophan anyway).
  • Bromantane 50 mg AM (DA-synthesis upregulation, no direct NMDA-system overlap).
  • Adamax / Semax / Selank (peptides, distinct mechanisms).
  • BPC-157, TB-500, GHK-Cu (peripheral peptides).
  • Cerebrolysin (theoretical convergence — both enhance plasticity, but via different routes; no human stack data; default to cycling separately).
▸ Drug interactions deep dive
  • CYP enzymes: not publicly characterized in detail. Glutamic-acid-derived structure suggests low CYP involvement (zwitterionic amino-acid analogs typically don't transit CYPs heavily) but this is inference, not data. Treat as unknown.
  • Norepinephrine reuptake inhibition at >100 mg: at supratherapeutic doses, theoretical interaction with SNRI/SSRI/TCA antidepressants, MAOIs (do not combine), stimulants (additive sympathomimetic load).
  • Oral contraceptives: no DDI study; assume no induction effect, but unconfirmed.
  • Anticonvulsants: theoretical antagonism if dosing high enough to lower seizure threshold; no clinical data.
  • No QT-prolongation signal flagged in Phase 1.
▸ Pharmacogenomics
  • GRIN1 (GluN1 subunit gene): neboglamine binds the GluN1 subunit's ligand-binding domain; theoretical PGx relevance for GRIN1 polymorphisms exists but no published stratification data.
  • GRIN2A, GRIN2B: same theoretical relevance; no data.
  • CYP-related: minimal — CYP involvement in metabolism is not well characterized; CYP2D6 PM status (Dylan's Nordic ancestry, ~5-10% prior) is unlikely to be material.
  • Practical: minimal actionable pharmacogenomics data exists for neboglamine. 23andMe results are unlikely to change a SKIP-FOR-NOW verdict in 2026.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem Umbrella Labs (umbrellalabs.is) $59.99 / 1 g HCl powder; also 30 mg/mL × 30 mL liquid; 10 mg × 60 caps Medium LC-MS COA dated 2025-12-05 visible on product page, ≥99% purity claim. Multiple format options (powder/liquid/capsule). Most consumer-facing of the available vendors.
Research-chem InvivoChem (invivochem.com) Variable per gram Medium-high Lab-grade research supplier; sells to academic + biotech accounts; published Nature 2024/2025 references in their portfolio. CAS-confirmed.
Research-chem Smolecule, AbMole, GlpBio, TargetMol, BenchChem, MedChemExpress $variable Higher (lab-grade) Legitimate research suppliers; institutional-account preference; per-gram pricing oriented toward research labs not consumers.
Avoid Random reseller / unverified site — Untestable Identity-unconfirmed product is a hard skip — at 25-50 mg therapeutic dose, vendor mislabeling has tight margins.
Clinical None available — — No active clinical trial enrollment; no Rx pathway anywhere in the world; investigational status with no approval timeline.

Critical sourcing notes:

  1. COA verification mandatory. Two CAS numbers are in circulation: 163000-63-3 (free acid) and 2759182-59-5 (HCl salt). Most research-chem product is the HCl salt — confirm CAS on the COA matches the product label. Free-acid product has poor solubility and would dose differently per mg.
  2. Neboglamine is a relatively obscure research-chem. Vendor identity confirmation matters more than usual — a COA from a single in-house lab is weaker evidence than a third-party (Janoshik, Anresco, etc.) verification, but third-party COAs are not standard for this compound.
  3. Customs / legal: not scheduled in any major jurisdiction. US: gray-area research-chem; FDA generally does not pursue research-chem personal use, but the framing is fragile.
  4. Cost-per-dose math: at $60/g and a 25-50 mg/day protocol, 1 gram = ~20-40 doses = $1.50-3.00 per day. Cheap relative to TAK-653 or Cerebrolysin.
  5. Vendor anecdote tier: Umbrella Labs is consumer-friendly; the academic-grade suppliers (InvivoChem, Smolecule, etc.) are more reliable but harder for a non-institutional buyer to access.
▸ Biomarkers to track (deep)

Baseline (before starting, for any research-chem trial)

  • Mood/cognition battery (PHQ-9, GAD-7, CNS Vital Signs or Cambridge Brain Sciences, self-rated cognitive output) — establish 2-week pre-baseline.
  • Sleep-onset latency, sleep duration, sleep quality (Oura/Whoop).
  • Resting heart rate, blood pressure.
  • Liver panel, CBC.
  • MMA-specific: serum NfL if accessible — same biomarker as recommended for TAK-653 trial; pre-trial baseline for the subconcussive-interaction question.
  • EEG baseline if accessible — given the (theoretical) seizure-threshold concern, a clean baseline EEG would be a defensible add. Most consumer EEG (Muse, Emotiv) is not clinical-grade for this use — would need a clinical EEG.

During use (week 1-2 if running pilot)

  • Mood/cognition battery weekly.
  • Sleep metrics daily.
  • HR/BP weekly.
  • Subjective: any aura-flavored phenomena (déjà vu spikes, brief speech arrest, focal sensory weirdness), headache pattern, anxiety creep, irritability, paradoxical low mood.

Post-cycle (1+ week off-drug)

  • Repeat mood/cognition battery — does benefit persist or dissipate?
  • Sleep metrics return to baseline?
  • Optional: repeat NfL if ran baseline.
▸ Controversies / open debates Live debate
  • Phase 2 stall = silent failure? The most important open question. Rottapharm's neboglamine program reached Phase 2 by 2010-2015 and has not produced a public efficacy readout in 10+ years. Possible explanations: (a) program quietly killed after unfavorable Phase 2 readout (most parsimonious), (b) funding/strategic deprioritization at Rottapharm/Madaus and the IP is in cold storage, (c) regulatory/manufacturing barrier rather than efficacy. Without a public statement or peer-reviewed paper, this cannot be resolved — but the longer the silence, the more likely (a) becomes.
  • "Glycine-site PAM" as a category has a mixed-to-poor track record. Bitopertin (Roche, GlyT1) failed Phase 3 schizophrenia. Rapastinel/GLYX-13 (functional partial agonist at the glycine site, the most-hyped of the class) failed Phase 3 MDD. Iclepertin Phase 3 readouts pending. Luvadaxistat Phase 2 mixed. The clean translation from preclinical NMDA-hypofunction-correction to human clinical efficacy has been repeatedly unsuccessful. Neboglamine inherits this prior.
  • "PAM at an allosteric site distinct from the glycine site" — this is the cleanest mechanistic claim for neboglamine and the basis for any "this one is different" argument. Whether it actually translates to a different clinical profile from glycine-site agonists/GlyT1 inhibitors is the central empirical question that hasn't been answered.
  • NMDA potentiation in healthy adults: actually a good idea? The schizophrenia logic is "correct NMDA hypofunction → restore cognition." In healthy adults with normal NMDA tone, raising NMDA tone may produce no benefit (not hypofunctional to begin with) or may overshoot (excitatory tone too high → anxiety, sleep disruption, theoretical excitotoxicity). Modafinil and bromantane work in healthy adults via different mechanisms because they target real bottlenecks (orexin/histamine for modafinil, dopamine synthesis for bromantane). The case that neboglamine should help healthy 20-year-olds is weaker than the case that it should help schizophrenia patients.
  • Subconcussive impact + NMDA potentiation interaction. Same theoretical concern as TAK-653; arguably worse because NMDA receptors are the primary mediator of glutamate excitotoxicity (AMPA potentiates the trigger; NMDA potentiation amplifies the calcium influx that does the damage). Activity-dependent PAM mechanism should limit the exposure, but no clinical data in contact-sport athletes. For Dylan specifically this is the most material concern.
  • Vendor "phase 1" listing on Penchant Research Library — disagrees with AdisInsight/Synapse "Phase 2 highest reached." The discrepancy reflects either (a) Penchant lagging the public record, or (b) Penchant interpreting "Phase 2 program stalled, not formally discontinued" differently. Treat AdisInsight/Synapse as the more authoritative source.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW, verdict-confidence MEDIUM. Mechanism is theoretically interesting (only allosteric PAM at the NMDA glycine co-agonist site to reach Phase 2), but no published cognitive-enhancement data in healthy adults, Rottapharm program stalled at Phase 2 for 10+ years without public readout (Bayesian concern for silent failure), encyclopedia's prior flag against TAK-653 + neboglamine stack stands, MMA subconcussive impact + NMDA potentiation interaction is theoretically more concerning than for TAK-653 (NMDA is the primary excitotoxicity mediator). Verdict would upgrade to WATCH-LIST if a Phase 2 cognitive readout is published with positive signal AND independent vendor product becomes verifiable; would upgrade to OPTIONAL-ADD only after FDA-pathway revival or replication by an unaffiliated group; would stay SKIP-FOR-NOW if no further development announcements appear by 2027.
▸ Open questions / gaps Open
  • What did the Phase 2 schizophrenia trial actually show? No public cognitive-endpoint data. The "preliminary findings support antidepressant effect" press-release language is the entire public-domain readout.
  • Does the activity-dependent PAM mechanism actually translate to a different clinical profile from glycine-site agonists or GlyT1 inhibitors that have repeatedly failed in pivotal trials? Untested in publicly-available data.
  • Long-term safety beyond ~weeks-to-months. No human data exists.
  • Does neboglamine raise seizure threshold or lower it? Theoretical raising of cortical excitability suggests lowering; the activity-dependent mechanism should limit the effect; no clinical data.
  • Subconcussive impact / contact-sport interaction. Untested; no path to resolve in 2026.
  • Is the development program definitively dead? No public statement. Rottapharm SpA has changed corporate hands (Madaus Pharma, Meda Pharmaceuticals, Mylan, Viatris timeline) — IP may be sitting unmonetized. A revival is possible but unannounced.
  • Pharmacogenomics — does GRIN1/GRIN2 genotype predict response? Untested. 23andMe is unlikely to provide actionable data.
  • At what dose does the weak NRI activity become clinically meaningful? ">100 mg" is the published threshold; below this, the mechanism should be NMDA-dominant. Not characterized in detail.
  • Why did the cocaine dependence indication become "inactive"? No public statement. Same Bayesian concern as the schizophrenia stall.
▸ Sources (full, with our context)
Back to compact view